The Lymphoma Translational Research Laboratory clinicians and scientists are focusing on studying the biology of B-cell and T-cell malignancies in an attempt to develop novel therapeutic strategies and/or biomarkers that can be used as surrogate markers of response. Using laboratory models, the research program aims to understand how the patient’s immune system and biologically designed therapies—monoclonal antibodies, immunomodulatory drugs or small molecules—interact with lymphoma cells.
The Lymphoma Translational Research Laboratory focuses on three major areas:
- Understanding the molecular basis for developing resistance to rituximab in patients with B-cell lymphoma
- Developing strategies to enhance the anti-tumor activity of rituximab and other monoclonal antibodies against lymphoma, using targeted specific molecules
- Identifying of biomarkers of response to current available therapies in patients with B-cell lymphoma
As treatment options for patients with lymphomas and related neoplasms become more diverse and complex, it is imperative to identify and validate biomarkers that can be utilized to predict response to a given specific therapy. Tailoring the selection of a specific treatment based on biomarkers has the potential to increase the percentage of patients who will respond to that treatment and who are most likely to gain clinical benefit.
In collaboration with the members of the Lymphoma Section and the Departments of Medicine and Immunology we have been able to establish a prestigious and scientifically respected Lymphoma Translational Research Program that is actively contributing to the field of novel “targeted” therapies of hematologic malignancies and is capable of advancing “bench” findings into rationally designed clinical trials for patients suffering from lymphoma and related neoplasms.